Psyence Biomedical Ltd. (PBM)

CA — Healthcare Sector
Peers:

Automate Your Wheel Strategy on PBM

With Tiblio's Option Bot, you can configure your own wheel strategy including PBM - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol PBM
  • Rev/Share 0.0
  • Book/Share -4.5354
  • PB -1.5296
  • Debt/Equity -1.9926
  • CurrentRatio 0.6394
  • ROIC -0.5074

 

  • MktCap 4046235.7574
  • FreeCF/Share -0.0024
  • PFCF -6083.2844
  • PE -0.078
  • Debt/Assets 1.1098
  • DivYield 0
  • ROE 38.8945

 

  • Rating C
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 1
  • P/B Score 1
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

Psyence BioMed Announces Effective Date for 1-for-7.97 Reverse Stock Split
PBM
Published: May 01, 2025 by: Newsfile Corp
Sentiment: Neutral

New York, New York--(Newsfile Corp. - May 1, 2025) - Psyence Biomedical Ltd. (NASDAQ: PBM) ("Psyence BioMed" or the "Company") today announced the effective date of its 1-for-7.97 share consolidation (reverse stock split) of the Company's issued and outstanding common shares.

Read More
image for news Psyence BioMed Announces Effective Date for 1-for-7.97 Reverse Stock Split
Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, names Albert P. Garcia-Romeu, Ph.D.
PBM, PSYGF
Published: March 10, 2025 by: GlobeNewsWire
Sentiment: Neutral

TORONTO, March 10, 2025 (GLOBE NEWSWIRE) -- Psyence Group Inc ("Psyence Group" or the "Company") (CSE: PSYG) is pleased that its NASDAQ-listed associate, Psyence Biomedical Ltd (NASDAQ: PBM) ("PBM" or "Psyence Biomed"), has announced that it will work closely with Albert P. Garcia-Romeu, Ph.D.

Read More
image for news Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, names Albert P. Garcia-Romeu, Ph.D.
Psyence Biomed Names Albert P. Garcia-Romeu, Ph.D.
PBM
Published: February 26, 2025 by: GlobeNewsWire
Sentiment: Neutral

NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed” or the “Company”) today announced that it will work closely with Albert P.

Read More
image for news Psyence Biomed Names Albert P. Garcia-Romeu, Ph.D.

About Psyence Biomedical Ltd. (PBM)

  • IPO Date 2021-12-10
  • Website https://www.psyencebiomed.com
  • Industry Biotechnology
  • CEO Dr. Neil Maresky M.D.
  • Employees 10
Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder, stress, grief, and adjustment disorder in the context of palliative care. It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer. The company is based in Toronto, Canada. Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc.